TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

By

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies

By

TScan Outlines 2022 Priorities as Programs Enter Clinic

By

TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

By

TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition

By

TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies

By

TScan Therapeutics to Participate in Upcoming Investor Conferences

By

TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

By

TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

By

TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

By